Does eplerenone have a future in the management of hypertension in Europe?
Gosse
P
P
Cardiologie/Hypertension Artérielle, Hypertension Unit Hôpital Saint André, Bordeaux University, 1 rue Jean Burguet, CHU Bordeaux, Bordeaux, France. philippe.gosse@chu-bordeaux.fr
Macfadyen
R J
RJ
D002986:Clinical Trials as Topic; D016527:Drug Costs; D000077545:Eplerenone; D005060:Europe / Q000453:epidemiology; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D000451:Mineralocorticoid Receptor Antagonists / Q000191:economics / Q000627:therapeutic use*; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D006113:United Kingdom / Q000453:epidemiology
D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone